Arikace is an antibiotic, proven effective against cf lung infections
And it met its primary endpoint. So, those of us that have been here for a while know how to recognize a trial failure. This was a success by any measure! As a rotational antibiotic, Arikace will be used in a majority of CF patients worldwide. Positive phase 3 results make Insmed a billion dollar buyout candidate today. Sellers made a mistake, but at least Terry got to cover.
Here's what insm is all about:
Insmed's proprietary liposomal technology is designed specifically for delivery of pharmaceuticals to the lung. We believe this liposomal technology provides for potential improvements to the conventional inhalation methods of delivering drug to the pulmonary system. These potential advantages include improvements in efficacy, safety and patient convenience.